PROSPECTUS |
Filed Pursuant to Rule 424(b)(4)
Registration No. 333-273370
|
SenesTech, Inc.
450,306 Shares of Common Stock and Accompanying
Series D Warrants to Purchase up to 450,306 Shares of Common Stock and Series E Warrants to Purchase up to 450,306 Shares of Common Stock
Pre-Funded Warrants to Purchase up to 3,395,848
Shares of Common Stock and Accompanying Series D Warrants to Purchase up to 3,395,848 Shares of Common Stock and Series E Warrants to
Purchase up to 3,395,848 Shares of Common Stock
3,395,848 Shares of Common Stock Underlying
the Pre-Funded Warrants, 3,846,154 Shares of Common Stock Underlying the Series D Warrants and 3,846,154 Shares of Common Stock Underlying
the Series E Warrants
Placement Agent Warrants to Purchase up
to 288,462 Shares of Common Stock
288,462 Shares of Common Stock Underlying the
Placement Agent Warrants
We are offering 450,306 shares of our common stock, par value $0.001
per share (“Common Stock”), together with Series D warrants (the “Series D Warrants”) to purchase up to 450,306
shares of our Common Stock and Series E warrants (the “Series E Warrants” and, together with the Series D Warrants, the
“Series Warrants”) to purchase up to 450,306 shares of our Common Stock at a combined public offering price of $1.30
per share of Common Stock and the accompanying Series D Warrant and Series E Warrant (and the shares of Common Stock that are issuable
from time to time upon exercise of the Series Warrants) pursuant to this prospectus. Each share of Common Stock is being offered together
with a Series D Warrant to purchase one share of Common Stock and a Series E Warrant to purchase one share of Common Stock. The shares
of Common Stock and Series Warrants will be issued separately but must be purchased together. The Series Warrants have an exercise price
of $1.30 per share and will be exercisable upon issuance. The Series D Warrants will expire five years from the date of issuance, and
the Series E Warrants will expire 18 months from the date of issuance.
We are also offering to those purchasers whose purchase of our Common
Stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation
of this offering, pre-funded warrants to purchase up to 3,395,848 shares of our Common Stock (the “Pre-Funded Warrants”).
Each Pre-Funded Warrant is being issued together with the same Series Warrants described above being issued with each share of Common
Stock. The purchase price of each Pre-Funded Warrant will equal the price per share at which shares of our Common Stock are being sold
to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will equal $0.0001 per share of Common
Stock. Each Pre-Funded Warrant will be exercisable upon issuance and may be exercised at any time until all of the Pre-Funded Warrants
are exercised in full. The Pre-Funded Warrants and Series Warrants must be purchased together but are immediately separable and will be
issued separately in this offering. Pursuant to this prospectus, we are also offering the shares of Common Stock issuable upon the exercise
of the Series Warrants and the Pre-Funded Warrants. This prospectus also relates to the offering of Placement Agent Warrants (as such
term is defined below) to purchase up to 288,462 shares of Common Stock and 288,462 shares of Common Stock issuable upon exercise of the
Placement Agent Warrants.
Each Pre-Funded Warrant is exercisable for one
share of our Common Stock (subject to adjustment as provided for therein), provided that the holder will be prohibited from exercising
Pre-Funded Warrants for shares of our Common Stock if, as a result of such exercise, the holder, together with its affiliates, would own
more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any holder may increase such percentage
to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after
such notice to us.
We have engaged H.C. Wainwright & Co., LLC
(the “Placement Agent”) to act as our exclusive placement agent in connection with the securities offered by this prospectus.
The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus.
The Placement Agent is not purchasing or selling any of the securities we are offering, and the Placement Agent is not required to arrange
the purchase or sale of any specific number of securities or dollar amount. There will only be one closing in connection with this offering.
The combined public offering price per share (or Pre-Funded Warrant) and Series Warrants will be fixed for the duration of this offering.
Our Common Stock is listed on Nasdaq under the
symbol “SNES.” There is no established public trading market for the Pre-Funded Warrants or Series Warrants, and we do not
expect a market to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants or Series Warrants on any
national securities exchange. Without an active trading market, the liquidity of the Series Warrants and the Pre-Funded Warrants will
be limited.
Effective November 16, 2023, we amended our amended
and restated certificate of incorporation to effect a 1-for-12 reverse split of our issued and outstanding shares of our Common Stock.
All share and per share data in this prospectus gives effect to the reverse stock split. Documents incorporated by reference into this
prospectus that were filed prior to November 16, 2023 do not give effect to the reverse stock split.
On November 27, 2023, the last reported sale price
for our Common Stock on Nasdaq was $1.88 per share. The public offering price per share of Common Stock and/or any Pre-Funded Warrant,
together with the Series Warrants that accompany Common Stock or a Pre-Funded Warrant is $1.30 (less $0.0001 per Pre-Funded Warrant).
We have agreed to pay the Placement Agent the
Placement Agent fees set forth in the table below. We will bear all costs associated with this offering. See “Plan of Distribution”
on page 20 of this prospectus for more information regarding these arrangements.
| |
Per Share and Series Warrants | | |
Per Pre-Funded Warrant and Series Warrants | | |
Total | |
Public offering price(1) | |
$ | 1.30 | | |
$ | 1.2999 | | |
$ | 5,000,000.20 | (4) |
Placement Agent fees(2) | |
$ | 0.0975 | | |
$ | 0.0975 | | |
$ | 375,000.02 | |
Proceeds, before expenses, to us(3) | |
$ | 1.2025 | | |
$ | 1.2024 | | |
$ | 4,625,000.18 | |
| (1) | Includes $0.125 per warrant for each accompanying Series Warrant. |
| (2) | We
have agreed to (i) pay the Placement Agent a cash fee equal to 7.5% of the aggregate gross proceeds raised in this offering, (ii) pay
the Placement Agent a management fee equal to 1.0% of the aggregate gross proceeds raised in this offering, (iii) pay the Placement Agent
for non-accountable expenses in an amount up to $40,000 or 3% of the aggregate gross proceeds of this offering, whichever is less, (iv)
pay the Placement Agent for its reasonable and documented out-of-pocket expenses, including legal fees of up to $100,000, and (v) pay
the Placement Agent for its closing costs, including clearing fees, in an amount of up to $15,950 in connection with this offering. In
addition, we have agreed to issue to the Placement Agent or its designees as compensation in connection with this offering warrants (the
“Placement Agent Warrants”) to purchase a number of shares of Common Stock equal to 7.5% of the shares of Common Stock sold
in this offering (including the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants), at an exercise price of
$1.625 per share, which represents 125% of the combined public offering price per share and accompanying Series Warrants. See “Plan
of Distribution” for a description of the compensation to be received by the Placement Agent. |
| (3) | We
estimate the total expenses of this offering payable by us, excluding the placement agent fees, will be approximately $195,000. For more
information, see “Plan of Distribution.” |
| (4) | The
total public offering price assumes the full exercise of the Pre-Funded Warrants. |
This prospectus, including such information that
is incorporated by reference, contains summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All the summaries are qualified in their entirety by the actual documents. Copies
of some of the documents referred to herein have been filed or have been incorporated by reference as exhibits to the registration statement
of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading
“Where You Can Find Additional Information.”
Investing in our securities involves a high
degree of risk. Please read “Risk Factors” beginning on page 6 of this prospectus as well as any other risk factors
and other information contained in any other document that is incorporated by reference herein.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is
not permitted.
Delivery of the Common Stock, Pre-Funded Warrants and the Series Warrants
offered hereby is expected to be made on or about November 29, 2023, subject to satisfaction of certain customary closing conditions.
H.C.
Wainwright & Co.
The date of this prospectus is November 27, 2023
TABLE OF CONTENTS
You should read this prospectus and the information
incorporated by reference in this prospectus and any applicable prospectus supplement before making an investment in our securities. Please
read “Where You Can Find Additional Information” for more information. We have not and the Placement Agent has not authorized
anyone to provide you with any information or to make any representation, other than those contained in this prospectus and the documents
incorporated by reference or any free writing prospectus we have prepared. We take no responsibility for, and provide no assurance as
to the reliability of, any other information that others may give you. The information contained in this prospectus or incorporated by
reference in this prospectus is accurate only as of its date, or the date of the applicable document incorporated by reference, regardless
of the time of delivery of this prospectus or of any sale of our Common Stock and Series Warrants. Our business, financial condition,
results of operations and prospects may have changed since that date.
For investors outside the United States: We have
not done anything that would permit possession or distribution of this prospectus in any jurisdiction where action for that purpose is
required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves
about, and observe any restrictions relating to, the offering of securities and the distribution of this prospectus outside the United
States.
about
this prospectus
The registration statement of which this prospectus
forms a part that we have filed with the Securities and Exchange Commission (the “SEC”) includes exhibits that provide more
detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together
with the additional information described under the headings “Where You Can Find Additional Information” and “Incorporation
of Certain Information by Reference” before making your investment decision.
You should rely only on the information provided
in or incorporated by reference in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents
to which we otherwise refer you. We have not authorized anyone else to provide you with different information.
We have not authorized any dealer, agent or other
person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus
and any accompanying prospectus supplement or any related free writing prospectus. You must not rely upon any information or representation
not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement or any related free writing prospectus.
This prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus
and any accompanying prospectus supplement and any related free writing prospectus, if any, constitute an offer to sell or the solicitation
of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information contained in this prospectus and any accompanying prospectus supplement and any related free
writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information
we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though
this prospectus and any accompanying prospectus supplement and any related free writing prospectus is delivered or securities are sold
on a later date.
We have not done anything that would permit this
offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action for that purpose
is required, other than in the United States. You are required to inform yourself about and to observe any restrictions relating as to
this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.
We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.
You should also read and consider the information
in the documents to which we have referred you under the caption “Where You Can Find Additional Information” in this prospectus.
In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to
the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the
heading “Where You Can Find Additional Information.”
Unless
the context otherwise requires, references in this prospectus to “SenesTech,”
“we,” “us,” “our” and “our company” refer
to SenesTech, Inc., a Delaware corporation, and our subsidiaries. Our registered trademarks
currently used in the United States include SenesTech, our logo, including “Sound science.
Effective solutions.”, Contrapest, and Evolve. Solely for convenience, trademarks and
tradenames referred to in this prospectus may appear without the ® or ™ symbols,
but such references are not intended to indicate in any way that we will not assert, to the
fullest extent under applicable law, our rights, or that the applicable owner will not assert
its rights, to these trademarks and tradenames. We do not intend our use or display of other
companies’ trade names or trademarks to imply a relationship with, or endorsement or
sponsorship of us by, any other companies.
This prospectus contains and incorporates by reference
market data and industry statistics and forecasts that are based on our own internal estimates as well as independent industry publications
and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness
of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding
the market and industry data presented in this prospectus or the documents incorporated herein by reference, these estimates involve risks
and uncertainties and are subject to change based on various factors, including those discussed under the headings “Risk Factors”
in this prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors
should not place undue reliance on this information.
FORWARD-LOOKING
STATEMENTS
The statements contained in this prospectus that
are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). All statements other than statements of historical
facts contained or incorporated herein by reference in this prospectus, including statements regarding our future operating results, future
financial position, business strategy, objectives, goals, plans, prospects, markets, and plans and objectives for future operations, are
forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “suggests,” “targets,” “contemplates,”
“projects,” “predicts,” “may,” “might,” “plan,” “would,” “should,”
“could,” “can,” “potential,” “continue,” “objective,” or the negative of those
terms, or similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these
identifying words. Specific forward-looking statements in this prospectus include statements regarding:
| ● | our belief that ContraPest is unique in the pest control industry in attacking the reproductive systems
of both male and female rats; |
| ● | our belief that our field data shows ContraPest will result in a sustained reduction of the rat population; |
| ● | our belief that ContraPest is the first and only fertility control product designed to be non-lethal that
has been registered with the EPA for the management of rat populations; |
| ● | our expectation to continue to pursue regulatory approvals and amendments to the existing U.S. registration
for ContraPest and regulatory approvals for additional jurisdictions beyond the United States; |
| ● | our expectation that we will continue to seek to comply with completion of testing and certifications
required by the EPA and state registrations; |
| ● | our belief that we will continue to research and develop enhancements to ContraPest that align with our
target verticals and to develop other potential fertility control options for additional markets and species; |
| ● | our expectation regarding the number of shares outstanding after this offering; |
| ● | our expectation to continue to incur significant expenses and operating losses for the foreseeable future; |
| ● | our intention to use the net proceeds of this offering for general corporate purposes, which may include
research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions
of or investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements
to make any such acquisitions or investments as of the date of this prospectus; |
| ● | pending the intended uses described herein, our intention to invest the net proceeds of this offering
in short-term, investment grade, interest-bearing securities; and |
| ● | our belief that we do not anticipate paying any cash dividends to stockholders in the foreseeable future. |
These forward-looking statements are not guarantees
of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause
our own, or our industry’s, actual results to be materially different from the future results that are expressed or implied by these
statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a
variety of factors, including those discussed in Item 1A-“Risk Factors” of Part I of our Annual Report on Form 10-K, for the
year ended December 31, 2022, filed with the SEC on March 17, 2023, and those contained from time to time in our other filings with the
SEC. A number of factors could cause our actual results to differ materially from those indicated by the forward-looking statements. Such
factors include, among others, the following:
| ● | the successful commercialization of our products; |
| ● | market acceptance of our products; |
| ● | our financial performance, including our ability to fund operations; |
| ● | our ability to regain and maintain
compliance with Nasdaq’s continued listing requirements; and |
| ● | regulatory approval and regulation of our products and other factors and risks identified from time to
time in our filings with the SEC, including this prospectus. |
All forward-looking statements included herein
are based on information available to us as of the date hereof and speak only as of such date. Except as required by law, we undertake
no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. The forward-looking
statements contained in or incorporated by reference into this prospectus reflect our views as of the date of this prospectus about future
events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause our actual results, performance
or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance or achievements.
PROSPECTUS
SUMMARY
This summary highlights information contained
in other parts of this prospectus or incorporated by reference into this prospectus from our filings with the SEC, as described later
in the prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing
in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing
elsewhere in this prospectus, including the information incorporated by reference in this prospectus. You should read the entire prospectus
and the information incorporated by reference herein carefully, including the sections titled “Risk Factors,” “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” our audited financial statements and the related notes,
which are incorporated herein by reference from our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC
on March 17, 2023, and our unaudited financial statements and the related notes, which are incorporated herein by reference from our
Quarterly Report on Form 10-Q for the three month period ended March 31, 2023, filed with the SEC on May 11, 2023, our Quarterly Report
on Form 10-Q for the three and six month periods ended June 30, 2023, filed with the SEC on August 11, 2023, and our Quarterly Report
on Form 10-Q for the three and nine month periods ended September 30, 2023, filed with the SEC on November 9, 2023. Please read “Where
You Can Find Additional Information” on page 23 of this prospectus.
Our Company
Overview
We have developed and are commercializing
a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control. Although
there are myriad tools available to control rat populations, most rely on some form of lethal method to achieve effectiveness. Each of
these solutions is inherently limited by rat species’ resilience and survival mechanisms as well as their extraordinary rate of
reproduction. ContraPest®, our initial product, is unique in the pest control industry in affecting the reproductive systems
of both male and female rats, which our field data shows will result in a sustained reduction of the rat population.
Rats have plagued humanity throughout history.
They pose significant threats to the health and food security of many communities. In addition, rodents cause significant product loss
and damage through consumption and contamination. Rats also cause significant damage to critical infrastructure by burrowing beneath foundations
and gnawing on electrical wiring, insulation, fire proofing systems, electronics and computer equipment.
The most prevalent solution to rat infestations
is the use of increasingly powerful rodenticides. Although these solutions provide short term results, there are growing concerns about
secondary exposure and bioaccumulation of rodenticides in the environment, about the development of resistance over time, as well as concerns
about rodenticides that have no antidotes. The pest management industry and pest management professionals (“PMPs”) are being
asked by their customers and their communities for new solutions that are both effective and less toxic. Our goal is to provide customers
with not only a highly effective solution to combat their most difficult rat problems, but also offer a non-lethal option to serve customers
that are looking to decrease or remove the amount of rodenticide used in their pest control programs.
ContraPest is a liquid bait containing the active
ingredients 4-vinylcyclohexene diepoxide (“VCD”) and triptolide, a botanically derived compound. ContraPest limits reproduction
of male and female rats beginning with the first breeding cycle following consumption. ContraPest is currently being marketed for use
in controlling Norway and roof rat populations.
We began the registration process with the United
States Environmental Protection Agency (the “EPA”) for ContraPest on August 23, 2015. On August 2, 2016, the EPA granted an
unconditional registration for ContraPest as a Restricted Use Product (“RUP”), due to the need for applicator expertise for
deployment. On October 18, 2018, the EPA approved the removal of the RUP designation. In addition to the EPA registration of ContraPest
in the United States, ContraPest must obtain registration from the various state regulatory agencies prior to selling in each state. We
have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the
RUP designation.
We believe ContraPest is the first and only fertility
control product designed to be non-lethal that has been registered with the EPA for the management of rat populations. In case studies,
the addition of ContraPest to an integrated pest management system has improved the efficacy of the program up to 90% or more. ContraPest
is marketed to PMPs for incorporation into their services, as well as to end users who wish to perform their own pest management. We have
established a field sales force of six individuals who are arranged geographically as well as an e-commerce platform for direct sales
to consumers.
In the first quarter of 2022, we received approval
for and began marketing an additional dispenser format for ContraPest, the Elevate® Bait System with ContraPest. This system
provides an additional delivery method particularly appropriate for roof rat populations or any rat infestations that manifest above ground.
We expect to continue to pursue regulatory approvals
and amendments to the existing U.S. registration for ContraPest and regulatory approvals for additional jurisdictions beyond the United
States. On April 1, 2023 and May 18, 2023, we signed distribution agreements for the commercialization of ContraPest in the Maldives and
South Africa. In certain cases, our EPA and state registrations require completion of testing and certifications even though we have received
approval for the product or its labelling. We continue to seek to comply with these requirements.
We also continue to research and develop enhancements
to ContraPest that align with our target verticals and to develop other potential fertility control options for additional markets and
species. In November 2023, we launched our latest product, Evolve™, a soft bait containing the active ingredient cottonseed oil.
Evolve limits reproduction of male and female rats after one to two breeding cycles following consumption. Evolve is being developed
and marketed for use in controlling rat populations as a minimum risk pesticide under Section 25(b) of the U.S. Environmental Protection
Agency Federal Insecticide, Fungicide, and Rodenticide Act. We must obtain registration from the various state regulatory agencies that
do not accept the federal exemption. To date, we are authorized to sell Evolve in 15 states.
Our intellectual property portfolio supporting
ContraPest consists of nine international patent filings (in the United States, Europe, Canada, Brazil, Russia, Japan, Mexico, South
Korea and Australia) addressing the ContraPest compound. Claims directed toward the compound include composition-of-matter involving
a diterpenoid epoxide or salts thereof in combination with an organic diepoxide and use claims for inducing follicle depletion and for
reducing the reproductive capability of a mammalian animal or non-human mammalian population. Issued claims will have a patent term extending
to 2033 or longer based on patent term determinations in each of the filing countries. The novelty of ContraPest extends to its method
of field distribution and has required innovation to perfect the dosing of our product to rodents. We recently filed and received approval
for a U.S. patent application covering our liquid delivery system, which is used in our EVO bait station. The patent will expire in 2038.
We also recently filed a U.S. patent application covering our new soft bait product, Evolve.
For
a complete description of our business, financial condition, results of operations and other
important information, please read our filings with the SEC that are incorporated by reference
in this prospectus, including our Annual Report on Form 10-K for the year ended December
31, 2022; our Quarterly Reports on Form 10-Q for the periods ended March 31, 2023, June 30,
2023, and September 30, 2023; and our Current Reports on Form 8-K. For instructions on how
to find copies of these documents, please read “Where You Can Find Additional Information”
and “Incorporation of Certain Information by Reference.”
August 2023 Warrant Exercise and Issuance
On August 21, 2023, we entered into an inducement
offer letter agreement (the “Inducement Letter”) with a certain holder (the “Holder”) of certain of our existing
warrants to purchase up to (i) 6,453 shares of our common stock issued on October 26, 2020 and subsequently amended on November 16, 2022,
at an exercise price of $37.98 per share, as amended (the “October 2020 Warrants”), and (ii) 238,095 shares of common stock
issued on November 18, 2022, at an exercise price of $37.98 per share (the “November 2022 Warrants” and together with the
October 2020 Warrants, the “Existing Warrants). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing
Warrants to purchase an aggregate of 244,548 shares of our common stock at a reduced exercise price of $8.6424 per share in consideration
of our agreement to issue new common stock purchase warrants (the “New Warrants”), as described below, to purchase up to
an aggregate of 489,097 shares of our common stock (the “New Warrant Shares”).
Our aggregate gross proceeds from the exercise
of the Existing Warrants by the Holder were approximately $2.1 million, before deducting placement agent fees and other offering expenses
payable by us. The transactions contemplated pursuant to the Inducement Letter closed on August 24, 2023. We used the net proceeds from
the transaction for general corporate purposes.
In connection with the transaction, we also
issued to H.C. Wainwright & Co, LLC, as the exclusive placement agent in connection with the transaction, or to its designees, as
part of the placement agent’s compensation, warrants to purchase up to 12,229 shares of common stock, which have the same terms
as the New Warrants except the placement agent warrants have an exercise price equal to $10.8036 per share.
Nasdaq Listing
Minimum Public Float Requirement
On November 20, 2023, we received a letter
from the listing qualifications staff (the “Staff”) of Nasdaq providing notification that we no longer meet the minimum of
500,000 publicly held shares requirement pursuant to Nasdaq Listing Rule 5550(a)(4). In accordance with Nasdaq rules, we have until January
4, 2024 to provide the Staff with a specific plan to achieve and sustain compliance with all listing requirements of Nasdaq, including
the time frame for completion of this plan. After reviewing our plan, Nasdaq will provide written notice of their decision. If Nasdaq
does not accept our plan, we will have the opportunity to appeal their decision to a hearings panel.
Minimum Bid Price Requirement
As previously disclosed, on August 25, 2023,
we received a letter from the Staff of Nasdaq providing notification that the bid price for our Common Stock had closed below $1.00 per
share for the previous 30 consecutive business days and our Common Stock no longer met the minimum bid price requirement for continued
listing under Nasdaq Listing Rule 5550(a)(2). We were provided a period of 180 calendar days, or until February 21, 2024, in which to
regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of our Common Stock must be $1.00
per share or more for a minimum of 10 consecutive business days at any time before February 21, 2024.
If we do not regain compliance with Nasdaq
Listing Rule 5550(a)(2) by February 21, 2024, we may be eligible for an additional 180 calendar day compliance period. To qualify, we
would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards
for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and would need to provide written notice of our
intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it
appears to the Staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq would notify us that
our securities would be subject to delisting. In the event of such notification, we may appeal the Staff’s determination to delist
our securities, but there can be no assurance the Staff would grant our request for continued listing.
2023 Reverse Stock Split
On August 18, 2023, our stockholders
approved a reverse stock split of our Common Stock at a ratio of not less than 1-for-2 and not more than 1-for-12, with the actual
ratio to be determined by our board of directors (the “2023 Reverse Split”). On November 7, 2023, the Reverse Split
Committee of our board of directors approved a final split ratio of 1-for-12. Following such approval, we filed an amendment to our
amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect the 2023 Reverse
Split, with an effective time of 4:01 p.m., Eastern Time on November 16, 2023. The 2023 Reverse Split had the effect of reducing the
aggregate number of our outstanding shares of common stock from 5,899,060 shares on a pre-reverse split basis to a total of 492,293
shares outstanding on a post-reverse split basis. The number of authorized shares of our Common Stock will remain unchanged at
100,000,000 shares after the 2023 Reverse Split. For more information, see “Selected Financial Data.”
Unless otherwise noted, the financial information,
share numbers, option numbers, warrant numbers, other derivative security numbers and exercise prices appearing in this prospectus, including
those as of dates prior to the completion of the 2023 Reverse Split, have been adjusted to give effect to the 2023 Reverse Split. Documents
incorporated by reference into the registration statement of which this prospectus forms a part that were filed prior to November 16,
2023 do not give effect to the 2023 Reverse Split.
Corporate and Other Information
We were incorporated in Nevada in July 2004
and reincorporated in Delaware in November 2015. Our principal executive offices are located at 23460 N 19th Ave., Suite 110,
Phoenix, AZ 85027, and our telephone number is (928) 779-4143. Our corporate website address is www.senestech.com. The information
contained on or accessible through our website is not a part of this prospectus and should not be relied upon in connection with making
an investment decision.
SUMMARY
OF THE OFFERING
Common Stock
Offered |
|
450,306
shares of Common Stock on a “best efforts” basis. |
|
|
|
Description of Series Warrants |
|
We are issuing to purchasers of shares of our Common Stock and/or our
Pre-Funded Warrants in this offering a Series D Warrant to purchase one share of our Common Stock and a Series E Warrant to purchase one
share of our Common Stock for each share and/or Pre-Funded Warrant purchased in this offering for a combined public offering price of
$1.30 per share and accompanying Series Warrants (less $0.0001 per Pre-Funded Warrant). The Series Warrants have an exercise price
of $1.30 per share and will be exercisable upon issuance. The Series D Warrants will expire five years from the date of issuance, and
the Series E Warrants will expire 18 months from the date of issuance. The shares of Common Stock and Pre-Funded Warrants, and the accompanying
Series Warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately
separable upon issuance. See “Description of Securities We Are Offering — Series Warrants.” This prospectus also relates
to the offering of the shares of Common Stock issuable upon exercise of the Series Warrants and the Placement Agent Warrants.
|
|
|
|
Description of Pre-Funded Warrants |
|
We are also offering to each purchaser whose purchase of shares of
Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation
of this offering, Pre-Funded Warrants to purchase up to 3,395,848 shares of our Common Stock, in lieu of shares of Common Stock that would
otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding Common Stock. Subject to limited exceptions,
a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with
its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common
Stock outstanding immediately after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of our Common
Stock. The purchase price of each Pre-Funded Warrant will equal the price per share at which the shares of Common Stock are being sold
to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001 per share. See “Description
of Securities We Are Offering — Pre-Funded Warrants.” This offering also relates to the shares of Common Stock issuable upon
exercise of any Pre-Funded Warrants sold in this offering. |
|
|
|
Common Stock Outstanding Prior to This Offering |
|
492,293 shares. |
|
|
|
Common Stock to be Outstanding After This Offering |
|
942,599 shares (assuming
none of the Pre-Funded Warrants or Series Warrants issued in this offering or Placement Agent Warrants issued to the Placement Agent
or its designees as compensation in connection with this offering are exercised). |
Use of Proceeds |
|
We estimate that the net proceeds
to us from this offering will be approximately $4.2 million, after deducting the Placement Agent fees and estimated offering expenses
payable by us and assuming no exercise of the Series Warrants. We intend to use the net proceeds from the sale of the securities
for general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general
and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement
our business, although we have no present commitments or agreements to make any such acquisitions or investments as of the date of
this prospectus. Pending these uses, we intend to invest the funds in short-term, investment grade, interest-bearing securities.
It is possible that, pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for
us. See “Use of Proceeds.” |
|
|
|
Risk Factors |
|
You should carefully read and consider the information set forth under “Risk Factors” in this prospectus on page 6 and under similar headings in the documents incorporated by reference herein before deciding to invest in our securities. |
|
|
|
Lock-Up Agreements |
|
We and all of our executive officers and directors will enter into lock-up agreements with the Placement Agent. Under these agreements, we and each of these persons may not, without the prior written approval of the Placement Agent, offer, sell, contract to sell or otherwise dispose of or hedge Common Stock or securities convertible into or exchangeable for Common Stock, subject to certain exceptions. The restrictions contained in these agreements will be in effect for a period of 90 days after the date of the closing of this offering. For more information, see “Plan of Distribution.” |
|
|
|
Market for Common Stock |
|
Our Common Stock is listed on Nasdaq under the symbol “SNES.” |
|
|
|
Listing of Series Warrants |
|
We do not intend to list the Pre-Funded Warrants or the Series Warrants
on any securities exchange or nationally recognized trading system, including on Nasdaq. Without a trading market, the liquidity
of the Pre-Funded Warrants and the Series Warrants will be extremely limited. |
The
discussion above is based on 492,293 shares of our Common Stock outstanding as of November 20, 2023, which excludes the following as
of such date:
|
● |
37,357 shares of Common Stock issuable upon the
exercise of outstanding options with a weighted average exercise price of $122.51 per share; |
|
● |
596,508 shares of Common Stock issuable upon the
exercise of outstanding warrants with a weighted average exercise price of $22.69 per share; |
|
● |
41,392 shares of Common Stock available for grant
under our 2018 Equity Incentive Plan; |
|
● |
3,395,848 shares of our Common Stock issuable upon the exercise of
Pre-Funded Warrants to be issued in this offering; |
|
● |
7,692,308 shares of our Common Stock issuable
upon the exercise of Series Warrants to be issued in this offering; and |
|
● |
288,462 shares of Common Stock issuable upon the
exercise of the Placement Agent Warrants to be issued to the Placement Agent or its designees as compensation in connection with
this offering and pursuant to this prospectus. |
RISK
FACTORS
Investing in our securities, including
our Common Stock, our Pre-Funded Warrants and our Series Warrants, involves a number of risks. You should not invest unless you are able
to bear the complete loss of your investment. You should carefully consider the risks described below and discussed under the section
entitled “Risk Factors” in our most recent Annual Report on Form 10-K, which is incorporated herein by reference, together
with other information in this prospectus and the information and documents incorporated by reference in this prospectus, including our
future reports on Form 10-K, Form 10-Q and Form 8-K. The risks and uncertainties we have described below and under the section entitled
“Risk Factors” in our most recent Annual Report on Form 10-K incorporated herein by reference are not the only risks and
uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair
our business operations. If any of the following risks actually occur, our business could be harmed. In such case, the trading price
of our Common Stock could decline and investors could lose all or a part of the money paid to buy our securities. Our actual results
could differ materially from those anticipated in these forward-looking statements as a result of these and other factors.
See also the statements contained under the
heading “Forward-Looking Statements.”
Risks Related to the 2023 Reverse Split
and our Common Stock
If we are unable to continue as a going
concern, our securities will have little or no value.
We have incurred operating losses since our
inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. Based upon our current
operating plan, we expect that cash and cash equivalents at September 30, 2023, in combination with anticipated revenue and any additional
sales of our equity securities, will be sufficient to fund our current operations for at least the next three months. Our financial statements
as of December 31, 2022 and 2021 have been prepared under the assumption that we will continue as a going concern. Our independent registered
public accounting firm included in its opinion for the years ended December 31, 2022, and 2021 an explanatory paragraph referring
to our net loss from operations and net capital deficiency and expressing substantial doubt in our ability to continue as a going concern
without additional capital becoming available. If we encounter continued issues or delays in the commercialization of our fertility control
products or greater than anticipated expenses, our prior losses and expected future losses could have an adverse effect on our financial
condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a
going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient
amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty.
If we are unable to generate additional funds in the future through financings, sales of our products, licensing fees, royalty payments
or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. If we cannot continue
as a going concern, our stockholders would likely lose most or all of their investment in us.
We may not be able to comply with all
applicable listing requirements or standards of the Nasdaq Capital Market, and Nasdaq could delist our Common Stock.
Our Common Stock is listed on Nasdaq. In order
to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards. Previously, on September
26, 2018, March 20, 2019, February 20, 2020, March 2, 2022, and, most recently, on August 25, 2023, we received a letter from the listing
qualifications staff of Nasdaq providing notification that the bid price for our Common Stock had closed below $1.00 per share for the
previous 30 consecutive business days and our Common Stock no longer met the minimum bid price requirement for continued listing under
Nasdaq Listing Rule 5550(a)(2). In each case, in accordance with Nasdaq Listing Rule 5810(c)(3) (A), we had an initial period of 180
calendar days to regain compliance. To regain compliance, the closing bid price of our Common Stock had to be $1.00 per share or more
for a minimum of 10 consecutive business days at any time before the expiration of the initial compliance period.
In
the event that we are unable to regain compliance with Rule 5550(a)(2) during the initial compliance period, Nasdaq rules provide that
we may be eligible for an additional 180 calendar day compliance period. To qualify, we need to meet the continued listing requirement
for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the minimum bid price
requirement, and to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting
a reverse stock split, if necessary. On August 18, 2023, our stockholders approved a reverse stock split of our Common Stock at a ratio
of not less than 1-for-2 and not more than 1-for-12, with the actual ratio to be determined by our board of directors. On November 7,
2023, the Reverse Split Committee of our board of directors approved a final split ratio of 1-for-12. Following such approval, we filed
an amendment to our amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect
the reverse stock split, with an effective time of 4:01 p.m., Eastern Time on November 16, 2023. However, even if a stock split
has a positive effect on the market price for the common stock immediately following a reverse stock split, performance of our business
and financial results, general economic conditions and the market perception of our business, and other adverse factors which may not
be in our control, could lead to a decrease in the price of our common stock following the reverse stock split.
In addition, on November 20, 2023, we received
a letter from the Staff of Nasdaq providing notification that we no longer meet the minimum of 500,000 publicly held shares requirement
pursuant to Nasdaq Listing Rule 5550(a)(4). In accordance with Nasdaq rules, we have until January 4, 2024 to provide the Staff with
a specific plan to achieve and sustain compliance with all listing requirements of Nasdaq, including the time frame for completion of
this plan. After reviewing our plan, Nasdaq will provide written notice of their decision. If Nasdaq does not accept our plan, we will
have the opportunity to appeal their decision to a hearings panel.
In the event that we are unable to establish
compliance, or again become non-compliant, with Rule 5550(a)(2) and/or Rule 5550(a)(4) and cannot re-establish compliance within the
required timeframes, our Common Stock could be delisted from Nasdaq, which could have a material adverse effect on our financial condition
and which would cause the value of our Common Stock to decline. If our Common Stock is not eligible for listing or quotation on another
market or exchange, trading of our Common Stock could be conducted in the over-the-counter market or on an electronic bulletin board
established for unlisted securities such as the Pink Open Market operated by the OTC Markets Group, Inc. In such event, it would become
more difficult to dispose of, or obtain accurate price quotations for, our Common Stock, and there would likely be a reduction in our
coverage by security analysts and the news media, which could cause the price of our Common Stock to decline further. In addition, it
may be difficult for us to raise additional capital if we are not listed on a national securities exchange.
Our reverse stock splits may decrease the
liquidity of the shares of our Common Stock.
On
August 18, 2023, our stockholders approved a reverse stock split of our Common Stock at a
ratio of not less than 1-for-2 and not more than 1-for-12, with the actual ratio to be determined
by our board of directors. On November 7, 2023, the Reverse Split Committee of our board
of directors approved a final split ratio of 1-for-12 to regain compliance with the Nasdaq
minimum bid price requirement. The liquidity of the shares of our Common Stock may be affected
adversely by the reverse stock splits given the reduced number of shares that are outstanding
following the reverse stock splits. In addition, the reverse stock splits increase the number
of stockholders who own odd lots (less than 100 shares) of our Common Stock, creating the
potential for such stockholders to experience an increase in the cost of selling their shares
and greater difficulty effecting such sales.
Following a reverse stock split, the resulting
market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements
of those investors. Consequently, the trading liquidity of our Common Stock may not improve.
Although
we believe that a higher market price of our Common Stock may help generate greater or broader
investor interest, there can be no assurance that a reverse stock split, including the 2023
Reverse Split, will result in a share price that will attract new investors, including institutional
investors. In addition, there can be no assurance that the market price of our Common Stock
will satisfy the investing requirements of those investors. As a result, the trading liquidity
of our Common Stock may not necessarily improve. The primary intent for the 2023 Reverse
Split was that the anticipated increase in the price of our Common Stock immediately following
and resulting from a reverse stock split due to the reduction in the number of issued and
outstanding shares of Common Stock would help us meet the minimum bid price requirement pursuant
to Nasdaq Listing Rules. It cannot be assured that a reverse stock split, including the 2023
Reverse Split, will result in any sustained proportionate increase in the market price of
our Common Stock, which is dependent upon many factors, including our business and financial
performance, general market conditions, and prospects for future success, which are unrelated
to the number of shares of our Common Stock outstanding. It is not uncommon for the market
price of a company’s common stock to decline in the period following a reverse stock
split.
Our
share price is volatile, which could subject us to securities class action litigation, and your investment in our securities could decline
in value.
Our
stock could be subject to wide fluctuation in response to many risk factors listed in this section, and others beyond our control, including
the following:
| ● | market
acceptance and commercialization of our products; |
| ● | our
being able to timely demonstrate achievement of milestones, including those related to revenue
generation, cost control, cost effective source supply and regulatory approvals; |
| ● | our
ability to regain compliance with Nasdaq’s Listing Rules and remain listed on Nasdaq; |
| ● | results
and timing of our submissions with the regulatory authorities; |
| ● | failure
or discontinuation of any of our development programs; |
| ● | regulatory
developments or enforcements in the United States and non-U.S. countries with respect to
our products or our competitors’ products; |
| ● | failure
to achieve pricing acceptable to the market; |
| ● | regulatory
actions with respect to our products or our competitors’ products; |
| ● | actual
or anticipated fluctuations in our financial condition and operating results or our continuing
to sustain operating losses; |
| ● | competition
from existing products or new products that may emerge; |
| ● | announcements
by us or our competitors of significant acquisitions, strategic arrangements, joint ventures,
collaborations or capital commitments; |
| ● | issuance
of new or updated research or reports by securities analysts; |
| ● | announcement
or expectation of additional financing efforts, particularly if our cash available for operations
significantly decreases or if the financing efforts result in a price adjustment to certain
outstanding warrants; |
| ● | fluctuations
in the valuation of companies perceived by investors to be comparable to us; |
| ● | share
price and volume fluctuations attributable to inconsistent trading volume levels of our shares; |
| ● | disputes
or other developments related to proprietary rights, including patents, litigation matters
and our ability to obtain patent protection for our technologies; |
| ● | entry
by us into any material litigation or other proceedings; |
| ● | sales
of our Common Stock by us, our insiders or our other stockholders; |
| ● | exercise
of outstanding warrants; |
| ● | market
conditions for equity securities; and |
| ● | general
economic and market conditions unrelated to our performance. |
Furthermore,
the capital markets can experience extreme price and volume fluctuations that may affect the market prices of equity securities of many
companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions,
interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our Common Stock. In
addition, such fluctuations could subject us to securities class action litigation, which could result in substantial costs and divert
our management’s attention from other business concerns, which could seriously harm our business. You may not realize any return
on your investment in us and may lose some or all of your investment.
Risks Related to this Offering
Management will have broad discretion as
to the use of proceeds from this offering and we may use the net proceeds in ways with which you may disagree.
We intend to use the net proceeds of this offering
for general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general
and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our
business, although we have no present commitments or agreements to make any such acquisitions or investments as of the date of this prospectus.
Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the value of our Common Stock. Accordingly, you will be relying on the judgment
of our management on the use of net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether
the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business
and cause the price of our Common Stock to decline.
Pending these uses, we intend to invest the funds
in short-term, investment grade, interest-bearing securities. It is possible that, pending their use, we may invest the net proceeds in
a way that does not yield a favorable, or any, return for us.
The public offering price is set by our
board of directors and does not necessarily indicate the actual or market value of our Common Stock.
Our board of directors approved the public offering price and other
terms of this offering after considering, among other things: the number of shares authorized in our amended and restated certificate
of incorporation; the current market price of our Common Stock; trading prices of our Common Stock over time; the volatility of our Common
Stock; our current financial condition and the prospects for our future cash flows; the availability of and likely cost of capital of
other potential sources of capital; the characteristics of interested investors and market and economic conditions at the time of the
offering. The offering price is not intended to bear any relationship to the book value of our assets or our past operations, cash flows,
losses, financial condition, net worth or any other established criteria used to value securities. The public offering price may not be
indicative of the fair value of the Common Stock.
Purchasers who purchase our securities in
this offering pursuant to a securities purchase agreement may have rights not available to purchasers without the benefit of a securities
purchase agreement.
In addition to rights and remedies available to
all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement
will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those
investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement, including the following:
(i) timely delivery of shares; (ii) agreement to not enter into variable rate financings for one year from closing, subject to certain
exceptions; (iii) agreement to not enter into any financings for 90 days from closing; and (iv) indemnification for breach of contract.
You may experience future dilution as
a result of future equity offerings and other issuances of our shares of Common Stock and other securities. In addition, this offering
and future equity offerings and other issuances of our shares of Common Stock or other securities may adversely affect our shares of
Common Stock.
In
order to raise additional capital, we may in the future offer additional shares of Common
Stock or other securities convertible into or exchangeable for shares of Common Stock at
prices that may be higher or lower than the price per share in this offering. We cannot assure
you that we will be able to sell shares or other securities in any other offering at a price
per share that is equal to or greater than the price per share paid by investors in this
offering, and investors purchasing shares or other securities in the future could have rights
superior to our existing stockholders.
Additionally, we are generally not
restricted from issuing additional securities, including shares of our Common Stock, securities that are convertible into or
exchangeable for, or that represent the right to receive, shares of our Common Stock or substantially similar securities. The
issuance of additional shares of our Common Stock in future offerings could be dilutive to stockholders, including investors in this
offering, if they do not invest in future offerings. Moreover, to the extent that we issue options or warrants to purchase, or
securities convertible into or exchangeable for, shares of our Common Stock in the future and those options, warrants or other
securities are exercised, converted or exchanged, stockholders may experience further dilution. In addition, the sale of shares in
this offering and any future sales of a substantial number of shares of Common Stock in the public market, or the perception that
such sales may occur, could adversely affect the price of our shares of Common Stock. We cannot predict the effect, if any, that
market sales of those shares of Common Stock or the availability of those shares of Common Stock for sale will have on the market
price of our shares of Common Stock.
There is no public market for the Pre-Funded
Warrants or the Series Warrants being offered in this offering.
There is no established public trading market
for the Pre-Funded Warrants or the Series Warrants being offered in this offering, and we do not expect a market to develop. In addition,
we do not intend to apply to list the Pre-Funded Warrants or the Series Warrants on any securities exchange or nationally recognized trading
system, including Nasdaq. Without an active market, the liquidity of the Pre-Funded Warrants or the Series Warrants will be limited.
Holders of Pre-Funded Warrants or Series
Warrants purchased in this offering will have no rights as Common Stockholders until such holders exercise such warrants and acquire our
Common Stock.
Until holders of Pre-Funded Warrants or Series
Warrants acquire shares of our Common Stock upon exercise of the Pre-Funded Warrants or Series Warrants, as applicable, holders of Pre-Funded
Warrants or Series Warrants will have no rights with respect to the shares of our Common Stock underlying such Pre-Funded Warrants or
Series Warrants. Upon exercise of the Pre-Funded Warrants or Series Warrants, the holders will be entitled to exercise the rights of a
Common Stockholder only as to matters for which the record date occurs after the exercise date.
Provisions of the Series Warrants and Pre-Funded
Warrants offered by this prospectus could discourage an acquisition of us by a third party.
In
addition to the discussion of the provisions of our amended and restated certificate of incorporation,
certain provisions of the Series Warrants and Pre-Funded Warrants offered by this prospectus
could make it more difficult or expensive for a third party to acquire us. Such Series Warrants
and Pre-Funded Warrants prohibit us from engaging in certain transactions constituting “fundamental
transactions” unless, among other things, the surviving entity assumes our obligations
under the Series Warrants and Pre-Funded Warrants. Further, the Series Warrants and Pre-Funded
Warrants provide that, in the event of certain transactions constituting “fundamental
transactions,” with some exception, holders of such the Series Warrants and Pre-Funded
Warrants will have the right, at their option, to require us to repurchase such the Series
Warrants and Pre-Funded Warrants at a price described in the Series Warrants and Pre-Funded
Warrants. These and other provisions of the Series Warrants and Pre-Funded Warrants offered
by this prospectus could prevent or deter a third party from acquiring us even where the
acquisition could be beneficial to you.
The Series Warrants in this offering are
speculative in nature.
The Series Warrants in this offering do not confer
any rights of Common Stock ownership on its holders, such as voting rights or the right to receive dividends, but rather merely represent
the right to acquire shares of Common Stock at a fixed price, as the case maybe. In addition, following this offering, the market value
of the Series Warrants, if any, is uncertain and there can be no assurance that the market value of the Series Warrants will equal or
exceed their imputed offering price and consequently, whether it will ever be profitable for holders of the Series Warrants to exercise
such warrants. The Series Warrants will not be listed or quoted for trading on any market or exchange.
We do not intend to pay any cash dividends
on Common Stock in the foreseeable future and, therefore, any return on your investment in Common Stock must come from increases in the
fair market value and trading price of Common Stock.
We do not intend to pay any cash dividends on
Common Stock in the foreseeable future and, therefore, any return on your investment in Common Stock must come from increases in the fair
market value and trading price of Common Stock.
This is a best efforts offering. No
minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business
plans, including our near-term business plans, nor will investors in this offering receive a refund in the event that we do not sell
an amount of securities sufficient to pursue the business goals outlined in this prospectus.
The Placement Agent has agreed to use its
reasonable best efforts to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any
of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. We may sell
fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors
in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued
operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our
operations in the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises
may not be available at all or available on terms acceptable to us.
There is no required minimum number of securities
that must be sold as a condition to completion of this offering, and we have not, nor will we, establish an escrow account, trust or
similar arrangement in connection with this offering. Because there is no minimum offering amount required as a condition to the closing
of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially
less than the maximum amounts set forth herein. Additionally, because there is no escrow account, trust or similar arrangement, and no
minimum offering amount, investors could be in a position where they have invested in us, but we are unable to fulfill our objectives
due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount,
any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we
would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances
whether during or after the offering.
USE
OF PROCEEDS
We estimate that the net proceeds from this offering will be approximately
$4.2 million based on the sale of 450,306 shares of Common Stock, Pre-Funded Warrants to purchase up to 3,395,848 shares of Common Stock
and accompanying Series Warrants at a combined public offering price of $1.30 per share of Common Stock (less $0.0001 per Pre-Funded Warrant)
and the accompanying Series Warrants, after deducting the Placement Agent fees and estimated offering expenses payable by us, and assuming
full exercise of the Pre-Funded Warrants for cash and no exercise of the Series Warrants being issued in this offering.
These estimates exclude the proceeds, if any,
from the exercise of the Series Warrants issued in this offering. We cannot predict when or if these Series Warrants will be exercised.
It is possible that these Series Warrants may expire and may never be exercised. Additionally, the Series Warrants contain a cashless
exercise provision that permit exercise of the Series Warrants on a cashless basis at any time where there is no effective registration
statement under the Securities Act of 1933, as amended, covering the issuance of the underlying shares.
We intend to use the net proceeds of this offering
for general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general
and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our
business, although we have no present commitments or agreements to make any such acquisitions or investments as of the date of this prospectus.
Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the value of our Common Stock. Accordingly, you will be relying on the judgment
of our management on the use of net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether
the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business
and cause the price of our Common Stock to decline.
Pending these uses, we intend to invest the funds
in short-term, investment grade, interest-bearing securities. It is possible that, pending their use, we may invest the net proceeds in
a way that does not yield a favorable, or any, return for us.
SELECTED
FINANCIAL DATA
Reverse Stock Split
On November 16, 2023,
we effected a 1-for-12 reverse stock split of our Common Stock (the “2023 Reverse Split”). The 2023 Reverse Split had the
effect of reducing our aggregate number of outstanding shares of Common Stock from 5,899,060 shares on a pre-reverse split basis to a
total of 492,293 shares outstanding on a post-reverse split basis. The total number of authorized shares of our common stock remained
unchanged at 100,000,000 shares after the 2023 Reverse Split. The par value per share of our common stock also remained unchanged.
The following selected
financial data has been derived from our audited financial statements included in our Annual Report on Form 10-K filed with the SEC on
March 17, 2023, and our unaudited financial statements included in our Quarterly Reports on Form 10-Q filed with the SEC on May 11, 2023,
August 11, 2023, and November 9, 2023, as adjusted to reflect the 2023 Reverse Split for all periods presented.
Our historical results
are not indicative of the results that may be expected in the future, and results of interim periods are not indicative of the results
for the entire year.
As Reported
| |
Years Ended December 31, | |
(in thousands, except share and per share amounts) | |
2022 | | |
2021 | |
Net loss and comprehensive loss | |
$ | (9,695 | ) | |
$ | (8,268 | ) |
Net loss per share, basic and diluted | |
$ | (15.50 | ) | |
$ | (14.77 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 625,401 | | |
| 559,591 | |
Common shares outstanding at year end | |
| 809,648 | | |
| 610,364 | |
| |
Three Months Ended
March 31, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (2,037 | ) | |
$ | (2,332 | ) |
Loss per share, basic and diluted | |
$ | (1.32 | ) | |
$ | (3.82 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 1,538,514 | | |
| 610,450 | |
Common shares outstanding at period end | |
| 2,107,339 | | |
| 610,614 | |
| |
Three Months Ended June 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (1,993 | ) | |
$ | (2,569 | ) |
Net loss per share, basic and diluted | |
$ | (0.70 | ) | |
$ | (4.21 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 2,860,874 | | |
| 610,635 | |
Common shares outstanding at period end | |
| 2,964,485 | | |
| 610,647 | |
| |
Six Months Ended
June 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (4,030 | ) | |
$ | (4,901 | ) |
Net loss per share, basic and diluted | |
$ | (1.83 | ) | |
$ | (8.03 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 2,208,162 | | |
| 610,543 | |
Common shares outstanding at period end | |
| 2,964,485 | | |
| 610,647 | |
| |
Three Months Ended
September 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (1,947 | ) | |
$ | (2,646 | ) |
Net loss per share, basic and diluted | |
$ | (0.47 | ) | |
$ | (4.33 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 4,176,592 | | |
| 610,648 | |
Common shares outstanding at period end | |
| 3,279,485 | | |
| 610,647 | |
Common
shares issued at period end (1) | |
| 5,899,060 | | |
| 610,647 | |
| |
Nine Months Ended September
30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (5,977 | ) | |
$ | (7,547 | ) |
Net loss per share, basic and diluted | |
$ | (1.97 | ) | |
$ | (12.36 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 3,037,790 | | |
| 610,578 | |
Common shares outstanding at period end | |
| 3,279,485 | | |
| 610,647 | |
Common
shares issued at period end (1) | |
| 5,899,060 | | |
| 610,647 | |
As Adjusted For One-For-Twelve Reverse
Stock Split
| |
Years Ended December 31, | |
(unaudited, in thousands, except share and per share amounts): | |
2022 | | |
2021 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (9,695 | ) | |
$ | (8,268 | ) |
Net loss per share, basic and diluted | |
$ | (186.00 | ) | |
$ | (177.24 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 52,116 | | |
| 46,632 | |
Common shares outstanding at year end | |
| 67,470 | | |
| 50,863 | |
| |
Three Months Ended
March 31, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (2,037 | ) | |
$ | (2,332 | ) |
Net loss per share, basic and diluted | |
$ | (15.84 | ) | |
$ | (45.84 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 128,209 | | |
| 50,870 | |
Common shares outstanding at period end | |
| 175,611 | | |
| 50,884 | |
| |
Three Months Ended
June 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (1,993 | ) | |
$ | (2,569 | ) |
Net loss per share, basic and diluted | |
$ | (8.40 | ) | |
$ | (50.52 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 238,406 | | |
| 50,886 | |
Common shares outstanding at period end | |
| 247,040 | | |
| 50,887 | |
| |
Six Months Ended
June 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (4,030 | ) | |
$ | (4,901 | ) |
Net loss per share, basic and diluted | |
$ | (21.96 | ) | |
$ | (96.36 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 184,013 | | |
| 50,878 | |
Common shares outstanding at period end | |
| 247,040 | | |
| 50,887 | |
| |
Three Months Ended
September 30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (1,947 | ) | |
$ | (2,646 | ) |
Net loss per share, basic and diluted | |
$ | (5.64 | ) | |
$ | (51.96 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 348,049 | | |
| 50,887 | |
Common shares outstanding at period end | |
| 273,290 | | |
| 50,887 | |
Common
shares issued at period end (2) | |
| 491,588 | | |
| 50,887 | |
| |
Nine Months Ended September
30, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | |
Net loss and comprehensive loss | |
$ | (5,977 | ) | |
$ | (7,547 | ) |
Net loss per share, basic and diluted | |
$ | (23.64 | ) | |
$ | (148.32 | ) |
Weighted-average common shares outstanding, basic and diluted | |
| 253,149 | | |
| 50,881 | |
Common shares outstanding at period end | |
| 273,290 | | |
| 50,887 | |
Common
shares issued at period end (2) | |
| 491,588 | | |
| 50,887 | |
| (1) | In connection with the August 2023 exercise
of the Existing Warrants discussed above under “Prospectus Summary—August 2023
Warrant Exercise and Issuance,” of the 5,899,060 shares issued, 2,619,575 shares were
held in abeyance and not considered outstanding until certain conditions were met, at which
time such shares would become outstanding. The shares held in abeyance were held in abeyance
until notice from the stockholder that the balance, or any portion thereof, may be issued
in compliance with a beneficial ownership limitation provision in the warrants. As of November
13, 2023, none of such shares were held in abeyance. |
| (2) | In connection with the August 2023 exercise
of the Existing Warrants discussed above under “Prospectus Summary—August 2023
Warrant Exercise and Issuance,” of the 491,588 shares issued, 218,298 shares were held
in abeyance and not considered outstanding until certain conditions were met, at which time
such shares would become outstanding. The shares held in abeyance were held in abeyance until
notice from the stockholder that the balance, or any portion thereof, may be issued in compliance
with a beneficial ownership limitation provision in the warrants. As of November 13, 2023,
none of such shares were held in abeyance. |
MARKET
PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS
Market Information
Our Common Stock is listed on Nasdaq under the
symbol “SNES.” A description of the Common Stock that we are issuing in this offering is set forth under the heading “Description
of Securities We Are Offering.” We do not intend to apply for the listing of the Pre-Funded Warrants or the Series Warrants that
are part of this offering on any national securities exchange.
The last reported sale price on Nasdaq for our
Common Stock on November 27, 2023 was $1.88 per share.
Holders
As
of November 20, 2023, we had 692 record holders of our Common Stock, and no preferred stock
issued and outstanding. The number of record holders was determined from the records of our
transfer agent and does not include beneficial owners of Common Stock whose shares are held
in the names of various security brokers, dealers, and registered clearing agencies. The
transfer agent of our Common Stock and publicly traded warrants is Transfer Online, Inc.
The transfer agent and registrar’s address is 512 SE Salmon Street, Portland, Oregon
97214.
Dividend Policy
We have never declared or paid any cash dividends
on our Common Stock. We do not anticipate paying any cash dividends to stockholders in the foreseeable future. In addition, any future
determination to pay cash dividends will be at the discretion of the board of directors and will be dependent upon our financial condition,
results of operations, capital requirements, and such other factors as the board of directors deem relevant.
DESCRIPTION
OF SECURITIES WE ARE OFFERING
The following is a summary of the material terms
of our Common Stock. For additional information about our authorized capital, including our Common Stock and our outstanding warrants
to purchase Common Stock, we refer you to our amended and restated certificate of incorporation and amended and restated bylaws that are
currently in effect, which are included herein as Exhibit 3.1 and Exhibit 3.2, respectively, and our filings with the SEC that are incorporated
by reference in this prospectus, including our Annual Report on Form 10-K for the year ended December 31, 2022. For instructions on how
to find copies of these documents, please read “Where You Can Find Additional Information” and “Incorporation of Certain
Information by Reference.”
General
The descriptions of our capital stock and certain
provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by
reference to the amended and restated certificate of incorporation and amended and restated bylaws that are currently in effect.
Our amended and restated certificate of incorporation
provides for Common Stock and preferred stock, the rights, preferences and privileges of which may be designated from time to time by
our board of directors.
Our authorized capital stock consists of 110,000,000
shares, all with a par value of $0.001 per share, of which 100,000,000 shares are designated as Common Stock and 10,000,000 shares are
designated as preferred stock.
As
of November 20, 2023, our Common Stock was held by approximately 692 stockholders of record.
As of November 20, 2023, we had 41,392 shares of our Common Stock reserved for issuance under
our 2018 Equity Incentive Plan.
Common Stock
The holders of our Common Stock are entitled to
one vote per share on all matters submitted to a vote of our stockholders. Subject to preferences that may be applicable to any preferred
stock outstanding at the time, the holders of outstanding shares of Common Stock are entitled to receive ratably any dividends declared
by our board of directors out of assets legally available therefor. In the event that we liquidate, dissolve or wind up, holders of our
Common Stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any
then outstanding shares of preferred stock. Holders of Common Stock have no preemptive or conversion rights or other subscription rights.
There are no redemption or sinking fund provisions applicable to the Common Stock. As discussed in “Risk Factors” above, certain
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent
a merger, acquisition or other change of control involving us that our stockholders may consider favorable. All outstanding shares of
Common Stock are fully paid and non-assessable.
Except as otherwise required by Delaware law,
all stockholder action, other than the election of directors or certain amendments of our amended and restated certificate of incorporation,
is taken by the vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled
to vote on the subject matter, at a meeting in which a quorum, consisting of a majority of the outstanding shares of Common Stock is present
in person or by proxy. The election of directors by our stockholders is determined by a plurality of the voting power of the shares present
in person or represented by proxy at the meeting and entitled to vote, at a meeting held for such purposes at which a quorum, consisting
of a majority of the outstanding shares of Common Stock, is present in person or by proxy. Certain amendments to our amended and restated
certificate of incorporation require the approval of holders of at least sixty-six and two-third percent (66 2/3%) of the voting power
of all then-outstanding shares of our Common Stock entitled to vote generally in the election of directors, voting together as a single
class.
We have never declared or paid any cash dividends
on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance
the growth and development of our business. We do not intend to pay cash dividends on our Common Stock for the foreseeable future. Any
future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among
other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and
other factors our board of directors may deem relevant.
The shares of Common Stock offered by this prospectus,
when issued and paid for, will also be fully paid and non-assessable.
Our Common Stock is listed on Nasdaq under the
symbol “SNES.”
The transfer agent and registrar for our Common
Stock is Transfer Online, Inc. The transfer agent and registrar’s address is 512 SE Salmon Street, Portland, Oregon 97214.
Series Warrants
The following summary of certain terms and
provisions of the Series Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the
provisions of the Series Warrants, the forms of which are filed as exhibits to the registration statement of which this prospectus forms
a part. Prospective investors should carefully review the terms and provisions of the forms of Series Warrant for complete descriptions
of the terms and conditions of the Series Warrants.
We are selling to investors in this offering of shares of our Common
Stock (or Pre-Funded Warrants), together with a Series D Warrant to purchase one share of our Common Stock and a Series E Warrant to purchase
one share of our Common Stock for each share of Common Stock (or Pre-Funded Warrant) purchased in this offering for a combined public
offering price of $1.30 (less $0.0001 per Pre-Funded Warrant).
The Series Warrants have an exercise price of $1.30 per share and will
be exercisable upon issuance. The Series D Warrants will expire five years from the date of issuance, and the Series E Warrants will expire
18 months from the date of issuance. No fractional shares of Common Stock will be issued in connection with the exercise of a Series Warrant.
In lieu of fractional shares, we will round up to the next whole share.
Subject to limited exceptions, a holder of Series
Warrants will not have the right to exercise any portion of its Series Warrants if the holder, together with its affiliates, would beneficially
own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of our Common Stock outstanding immediately
after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’
prior notice to us, the holder may increase or decrease the Beneficial Ownership Limitation, provided that in no event shall the Beneficial
Ownership Limitation exceed 9.99%.
The Series Warrants contain a “cashless
exercise” feature that allows holders to exercise the Series Warrants without a cash payment to us upon the terms set forth in the
Series Warrants, if, at the time of exercise there is no effective registration statement registering, or the prospectus contained therein
is not available for the issuance of the shares to the exercising Series Warrant holder.
In the case of certain fundamental transactions
affecting our company, a holder of Series Warrants, upon exercise of such Series Warrants after such fundamental transaction, will have
the right to receive, in lieu of shares of our Common Stock, the same amount and kind of securities, cash or property that such holder
would have been entitled to receive upon the occurrence of the fundamental transaction, had the Series Warrants been exercised immediately
prior to such fundamental transaction. In lieu of such consideration, a holder of Series Warrants may instead elect to receive a cash
payment based upon the Black-Scholes value of their Series Warrants.
The exercise price and number of the shares of
our Common Stock issuable upon the exercise of the Series Warrants will be subject to adjustment in the event of any stock dividends and
splits, recapitalization, reorganization or similar transaction, as described in the Series Warrants.
We do not intend to list the Series Warrants on
any securities exchange or nationally recognized trading system. Except as otherwise provided in the Series Warrants or by virtue of such
holder’s ownership of shares of our Common Stock, the holders of the Series Warrants do not have the rights or privileges of holders
of our Common Stock, including any voting rights, until they exercise their Series Warrants.
Pre-Funded Warrants
The following summary of certain terms and
provisions of Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the
provisions of the Pre-Funded Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus
forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete
description of the terms and conditions of the Pre-Funded Warrants.
Each Pre-Funded Warrant offered hereby will have
an initial exercise price per share equal to $0.0001. The Pre-Funded Warrants will be immediately exercisable and may be exercised at
any time until the Pre-Funded Warrants are exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise
is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common
Stock and the exercise price. The Pre-Funded Warrants will be issued separately from the accompanying Series Warrants and may be transferred
separately immediately thereafter.
The Pre-Funded Warrants will be exercisable, at
the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed above).
A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own
more than 4.99% of the outstanding Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from
the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s Pre-Funded
Warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this
offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding
Common Stock.
At any time, in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to
receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set
forth in the Pre-Funded Warrants.
Subject to applicable laws, a Pre-Funded Warrant
may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments
of transfer.
We do not intend to list the Pre-Funded Warrants
on any securities exchange or nationally recognized trading system. Except as otherwise provided in the Pre-Funded Warrants or by virtue
of such holder’s ownership of shares of our Common Stock, the holders of the Pre-Funded Warrants do not have the rights or privileges
of holders of our Common Stock, including any voting rights, until they exercise their Pre-Funded Warrants.
Placement Agent Warrants
We have also agreed to issue to the Placement Agent or its designees
as compensation in connection with this offering, the Placement Agent Warrants to purchase up to 288,462 shares of Common Stock at an
exercise price of $1.625 per share (representing 125% of the combined public offering price per share and accompanying Series Warrants).
The Placement Agent Warrants will expire five years from the commencement of sales in this offering. Except as provided above, the Placement
Agent Warrants will have substantially the same terms as the Series Warrants described herein. See “Plan of Distribution”
below.
Anti-Takeover Provisions
Certificate of Incorporation and Bylaws
Because our stockholders do not have cumulative
voting rights, our stockholders holding a majority of the outstanding shares of Common Stock outstanding will be able to satisfy the quorum
requirement and be able to elect all of our directors by a plurality of the voting power of the shares present in person or by proxy.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected
at a duly called meeting of stockholders and not by written consent. A special meeting of stockholders may be called by a resolution adopted
by a majority of our board, our chair of the board, our chief executive officer or the president in absence of the chief executive officer.
Any power of the stockholders to call a special meeting is specifically denied by the terms of our amended and restated certificate of
incorporation.
Our board of directors is divided into three classes
with staggered three-year terms. These provisions make it more difficult for our existing stockholders to replace our board of directors
as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to
retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect
a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to
issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to obtain control of us.
These provisions are intended to enhance the likelihood
of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that
may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited
acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect
of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes
in our control or management. Consequently, these provisions also may inhibit fluctuations in the market price of our stock that could
result from actual or rumored takeover attempts.
Section 203 of the Delaware General Corporation
Law
We are subject to Section 203 of the Delaware
General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder
for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:
| ● | Before such date, the board of directors of the corporation approved either the business combination or
the transaction that resulted in the stockholder becoming an interested stockholder; |
| ● | Upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding
for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those
shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have
the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
| ● | On or after such date, the business combination is approved by the board of directors and authorized at
an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-third
percent (66 2/3%) of the outstanding voting stock that is not owned by the interested stockholder. |
In general, Section 203 defines business combination
to include the following:
| ● | Any merger or consolidation involving the corporation and the interested stockholder; |
| ● | Any sale, lease, exchange, mortgage, transfer, pledge or other disposition of 10% or more of the assets
of the corporation involving the interested stockholder; |
| ● | Subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation
of any stock of the corporation to the interested stockholder; |
| ● | Any transaction involving the corporation that has the effect of increasing the proportionate share of
the stock or any class or series of the corporation beneficially owned by the interested stockholder; or |
| ● | The receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or
other financial benefits by or through the corporation. |
In general, Section 203 defines an “interested
stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of
the corporation.
Choice of Forum
Our amended and restated certificate of incorporation
provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on
our behalf; any action asserting a claim of a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders;
any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to the Delaware General
Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or any action or proceeding
asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.
However, this exclusive forum provision would
not apply to suits brought to enforce any duty or liability created by the Securities Exchange Act of 1934, as amended, or the rules and
regulations thereunder, or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, this provision may apply
to Securities Act claims and federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created
by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce this
provision and that our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.
PLAN
OF DISTRIBUTION
Pursuant
to an engagement agreement, dated August 29, 2022 and amended October 21, 2022 and November
11, 2022 (as amended, the “Engagement Agreement”), we have engaged H.C. Wainwright
& Co., LLC to act as our exclusive Placement Agent to solicit offers to purchase the
securities offered pursuant to this prospectus on a reasonable best efforts basis. The Engagement
Agreement does not give rise to any commitment by the Placement Agent to purchase any of
our securities, and the Placement Agent will have no authority to bind us by virtue of the
Engagement Agreement. The Placement Agent is not purchasing or selling any of the securities
offered by us under this prospectus, nor is it required to arrange for the purchase or sale
of any specific number or dollar amount of securities. This is a best efforts offering, and
there is no minimum offering amount required as a condition to the closing of this offering.
The Placement Agent has agreed to use reasonable best efforts to arrange for the sale of
the securities by us. Therefore, we may not sell all of the shares of Common Stock, Pre-Funded
Warrants and Series Warrants being offered. The terms of this offering were subject to market
conditions and negotiations between us, the placement agent and prospective investors. The
Placement Agent does not guarantee that it will be able to raise new capital in any prospective
offering. The Placement Agent may engage sub-agents or selected dealers to assist with the
offering.
Investors
purchasing securities offered hereby will have the option to execute a securities purchase
agreement with us. In addition to rights and remedies available to all purchasers in this
offering under federal securities and state law, the purchasers that enter into a securities
purchase agreement will also be able to bring claims of breach of contract against us. The
ability to pursue a claim for breach of contract is material to larger purchasers in this
offering as a means to enforce the following covenants uniquely available to them under the
securities purchase agreement: (i) a covenant to not enter into variable rate financings
for a period of one year following the closing of the offering, subject to an exception;
and (ii) a covenant to not enter into any equity financings for 90 days from closing of the
offering, subject to certain exceptions. The nature of the representations, warranties and
covenants in the securities purchase agreements shall include:
| ● | standard issuer representations and warranties
on matters such as organization, qualification, authorization, no conflict, no governmental filings required, current in SEC filings,
no litigation, labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws
such as the Foreign Corrupt Practices Act; and |
| ● | covenants regarding matters such as registration
of warrant shares, no integration with other offerings, filing of a Form 8-K to disclose entering into these securities purchase agreements,
no stockholder rights plans, no material nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing
of shares of Common Stock, and no subsequent equity sales for 90 days. |
We expect to deliver the securities being offered
pursuant to this prospectus on or about November 29, 2023. There is no minimum number of securities or amount of proceeds that is a condition
to closing of this offering.
Fees and Expenses
We
have agreed to pay the Placement Agent a cash fee equal to 7.5% of the aggregate gross proceeds
raised in this offering, its legal fees and expenses and other out-of-pocket expenses in
an amount up to $100,000 and for clearing fees, in an amount up to $15,950 in connection
with this offering. We have also agreed to pay the Placement Agent a management fee equal
to 1.0% of the gross proceeds raised in this offering and up to $40,000 or 3% of the aggregate
proceeds of this offering, whichever is less, for non-accountable expenses. We estimate the
total offering expenses of this offering that will be payable by us, excluding the placement
agent fees and expenses, will be approximately $195,000.
Placement Agent Warrants
In addition, we have agreed to issue to the Placement Agent or its
designees as compensation in connection with this offering the Placement Agent Warrants to purchase up to 288,462 shares of Common
Stock (which represents 7.5% of the aggregate number of shares of shares of Common Stock issued in this offering and issuable upon the
exercise of the Pre-Funded Warrants issued in this offering) with an exercise price of $1.625 per share (representing 125% of the combined
public offering price per share and accompanying Series Warrants). The Placement Agent Warrants will be exercisable upon issuance and
will expire five years from the commencement of sales in this offering. The Placement Agent Warrants and the shares issuable upon exercise
of the Placement Agent Warrants are registered on the registration statement of which this prospectus is a part. The form of the Placement
Agent Warrant has been included as an exhibit to this registration statement of which this prospectus forms a part.
Tail
We have also agreed to pay the Placement Agent a
tail fee equal to the cash and warrant compensation in this offering, if any investor, who was contacted or introduced to us by the Placement
Agent during the term of its engagement, provides us with capital in any public or private offering or other financing or capital raising
transaction during the 12-month period following expiration or termination of our engagement of the Placement Agent, other than certain
private placement transactions involving issuances of securities to an operating company or an owner of an asset in a business synergistic
with our business.
Regulation M
The Placement Agent may be deemed to be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale
of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities
Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act,
including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of
purchases and sales of our securities by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent
(i) may not engage in any stabilization activity in connection with our securities and (ii) may not bid for or purchase any of our securities
or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed
its participation in the distribution.
Indemnification
We
have agreed to indemnify the Placement Agent against liabilities relating to the offering
arising under the Securities Act and the Exchange Act, liabilities arising from breaches
of some or all of the representations and warranties contained in the Engagement Agreement,
and to contribute to payments that the Placement Agent may be required to make for these
liabilities.
Determination of Offering Price
Our Common Stock is currently traded on Nasdaq
under the symbol “SNES.” On November 27, 2023 the closing price of our Common Stock on Nasdaq was $1.88 per share.
There is a material disparity between the combined
public offering price of the shares of our Common Stock and accompanying Series Warrants and combined public offering price of the Pre-Funded
Warrants and accompanying Series Warrants being offered under this prospectus and the market price of the Common Stock at the date of
this prospectus. We believe that the market price of our Common Stock at the date of this prospectus is not the appropriate public offering
price for the shares of our Common Stock, or the Pre-Funded Warrants, because the market price is affected by a number of factors. The
final combined public offering price was determined by negotiation between us, the Placement Agent and the investors in this offering.
The principal factors considered by us and the Placement Agent in determining the final public offering price included:
| ● | the recent trading history of our Common Stock on Nasdaq, including market prices and trading volume of
our Common Stock; |
| ● | the current market price of our Common Stock on Nasdaq; |
| ● | the recent market prices of, and demand for, publicly traded Common Stock of generally comparable companies; |
| ● | the information set forth or incorporated by reference in this prospectus and otherwise available to the
Placement Agent; |
| ● | our past and present financial performance and an assessment of our management; |
| ● | our prospects for future earnings and the present state of our products; |
| ● | the current status of competitive products and product developments by our competitors; |
| ● | our history and prospects, and the history and prospects of the industry in which we compete; |
| ● | the general condition of the securities markets at the time of this offering; and |
| ● | other factors deemed relevant by the Placement Agent and us. |
The final combined public offering price stated
on the cover page of this prospectus should not be considered an indication of the actual value of the shares of Common Stock and accompanying
Series Warrants and/or the Pre-Funded Warrants and accompanying Series Warrants sold in this offering. That price is subject to change
as a result of market conditions and other factors and we cannot assure you that the shares of Common Stock and accompanying Series Warrants
and/or Pre-Funded Warrants and accompanying Series Warrants sold in this offering can be resold at or above the combined public offering
price.
Lock-Up Agreements
Our officers and directors, representing beneficial
ownership of 3.84% of our outstanding shares of Common Stock, have agreed with the Placement Agent to be subject to a lock-up period
of 90 days following the closing of this offering. This means that, during the applicable lock-up period, such persons may not offer
for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose
of, directly or indirectly, any shares of our Common Stock or any securities convertible into, or exercisable or exchangeable for, shares
of our Common Stock. Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions.
We have also agreed to similar lock-up restrictions on the issuance and sale of our securities for 90 days following the closing of this
offering, although we will be permitted to issue stock options or stock awards to directors, officers and employees under our existing
plans. The lock-up period is subject to an additional extension to accommodate for our reports of financial results or material news
releases. The Placement Agent may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.
Transfer Agent and Registrar
The transfer agent and registrar for our Common
Stock is Transfer Online, Inc.
Other Relationships
The Placement Agent and its affiliates have engaged,
and may in the future engage, in investment banking transactions and other commercial dealings in the ordinary course of business with
us or our affiliates. The Placement Agent has received, or may in the future receive, customary fees and commissions for these transactions.
In addition, in the ordinary course of their business
activities, the Placement Agent and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The Placement Agent and its affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments.
The Placement Agent acted as the placement agent
in connection with several private placements and registered offerings in the past three years and it received compensation for each such
offering. However, except as disclosed in this prospectus, we have no present arrangements with the Placement Agent for any further services.
Electronic Distribution
A prospectus in electronic format may be made
available on a website maintained by the Placement Agent and the Placement Agent may distribute prospectuses electronically. Other than
the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of
which this prospectus forms a part, has not been approved and/or endorsed by us or the Placement Agent and should not be relied upon by
investors.
Foreign Regulatory Restrictions on Purchase
of Securities Offered Hereby Generally
No action has been or will be taken in any jurisdiction
(except in the United States) that would permit a public offering of the securities offered by this prospectus, or the possession, circulation
or distribution of this prospectus or any other material relating to us or the securities offered hereby in any jurisdiction where action
for that purpose is required. Accordingly, the securities offered hereby may not be offered or sold, directly or indirectly, and neither
of this prospectus nor any other offering material or advertisements in connection with the securities offered hereby may be distributed
or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such country
or jurisdiction.
The Placement Agent may arrange to sell securities
offered by this prospectus in certain jurisdictions outside the United States, either directly or through affiliates, where they are permitted
to do so. See “Where You Can Find Additional Information.”
Nasdaq Listing
Our Common Stock is listed on Nasdaq under the
symbol “SNES.”
Amendments to Plan of Distribution
This prospectus may be amended or supplemented
from time to time, if required, to describe a specific plan of distribution.
LEGAL
MATTERS
The
validity of the securities being offered hereby will be passed upon for us by Greenberg Traurig,
LLP, Phoenix, Arizona. Haynes and Boone, LLP, New York, New York is acting as counsel for
the Placement Agent in connection with certain legal matters related to this offering.
EXPERTS
Our
financial statements as of December 31, 2022 and 2021, and for each of the two years in the period ended December 31, 2022, incorporated
by reference in this prospectus have been so incorporated in reliance on the report of M&K CPAS, PLLC, an independent registered
public accounting firm (which report contains an explanatory paragraph describing conditions that raise substantial doubt about our ability
to continue as a going concern, as described in Note 1 to the financial statements), given on the authority of said firm
as experts in auditing and accounting.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a web site that contains
reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically
with the SEC. The website address is www.sec.gov. The information on the SEC’s website is not part of this prospectus, and
any references to this website or any other website are inactive textual references only.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
We
“incorporate by reference” certain information into this registration statement, which means that we disclose important information
to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be
part of this prospectus, and relying on the Fixing America’s Surface Transportation Act, or the FAST Act, as a smaller reporting
company, subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained
in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in this prospectus modifies or replaces that statement.
We
incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Exchange Act prior to the termination of the offering, including documents we may file with the SEC after the date of the
initial registration statement and prior to effectiveness of the registration statement. We are not, however, incorporating by reference
any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed “filed”
with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to
Item 9.01 of Form 8-K. This prospectus and any amendments or supplements thereto incorporate by reference the documents set forth below
that have previously been filed with the SEC:
| ● | Our
Annual Report on Form
10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 17, 2023; |
|
● |
Our Quarterly
Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, filed with the SEC on May
11, 2023, August
11, 2023, and November 9, 2023,
respectively; |
|
● |
The portions
of our Definitive Proxy Statement on Schedule
14A that are deemed “filed” with the SEC, filed
with the SEC on April 28, 2023; |
|
● |
Our Current
Reports on Form 8-K filed with the SEC on January
5, 2023, February
16, 2023, April
12, 2023, April
24, 2023, June
27, 2023, August
21, 2023, August
22, 2023, August
28, 2023, November
15, 2023, and November
22, 2023; and |
| ● | The
description of our capital stock contained in our registration statement on Form
8-A filed with the SEC on November 7, 2016, including any amendments or reports filed
for the purpose of updating such description (including Exhibit
4.1 to our Amendment No. 1 to the Annual Report on Form
10-K/A for the fiscal year ended December 31, 2019, filed with the SEC on April 21, 2020). |
You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide
you with any information. You should not assume that the information incorporated by reference or provided in this prospectus is accurate
as of any date other than the date on the front of each document. You may request a free copy of any or all of the reports or documents
incorporated by reference in this prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents)
by writing or telephoning us at the following address:
SenesTech,
Inc.
23460
N 19th Ave., Suite 110
Phoenix,
AZ 85027
Attn:
Secretary
(928)
779-4143
We
also maintain a website at www.senestech.com where incorporated reports or other documents filed with the SEC may be accessed.
We have not incorporated by reference into this prospectus the information contained in, or that can be accessed through, our website,
and you should not consider it to be part of this prospectus.
SenesTech,
Inc.
450,306 Shares of Common Stock and Accompanying
Series D Warrants to Purchase up to 450,306 Shares of Common Stock and Series E Warrants to Purchase up to 450,306 Shares of Common Stock
Pre-Funded Warrants to Purchase up to 3,395,848
Shares of Common Stock and Accompanying Series D Warrants to Purchase up to 3,395,848 Shares of Common Stock and Series E Warrants to
Purchase up to 3,395,848 Shares of Common Stock
3,395,858 Shares of Common Stock Underlying
the Pre-Funded Warrants, 3,846,154 Shares of Common Stock Underlying the Series D Warrants and 3,846,154 Shares of Common Stock Underlying
the Series E Warrants
Placement Agent Warrants to Purchase up
to 288,462 Shares of Common Stock
288,462 Shares of Common Stock Underlying the
Placement Agent Warrants
PROSPECTUS
H.C.
Wainwright & Co.
November
27, 2023
SenesTech (NASDAQ:SNES)
Historical Stock Chart
From Apr 2024 to May 2024
SenesTech (NASDAQ:SNES)
Historical Stock Chart
From May 2023 to May 2024